ÔÆÌ⺣ - רҵÎÄÕ·¶ÀýÎĵµ×ÊÁÏ·ÖÏíÆ½Ì¨

µ±Ç°Î»ÖãºÊ×Ò³ > ÎÞÔ´Ò½ÁÆÆ÷е¼¼ÊõÎĵµºÍÉè¼Æµµ°¸²ÄÁÏÖ¸ÄÏ

ÎÞÔ´Ò½ÁÆÆ÷е¼¼ÊõÎĵµºÍÉè¼Æµµ°¸²ÄÁÏÖ¸ÄÏ

  • 62 ´ÎÔĶÁ
  • 3 ´ÎÏÂÔØ
  • 2025/5/1 14:35:59

taken from the final product or from materials processed in the same manner as the final product (if applicable provide LOT/REF. No., etc.)

¶Ô´Ó³ÉÆ·Öлò´ÓÒÔͬÑùµÄ·½Ê½½øÐд¦ÀíµÄ²ÄÁÏÖгé³öµÄ³ÉÆ·»ò´ú±íÐÔÑùÆ·¾ªÐѲâÊÔ(Èç¹ûÊÊÓÃ,ÌṩÅúºÅ/²Î¿¼±àºÅµÈµÈ)

??Rationale for the selection of the sample tested±»²âÑùÆ·Ñ¡ÔñµÄ»ù±¾Ô­Àí ??Statement on the sterile state of the test sample. If the test sample was not

sterilized, a rationale shall be given why sterilization has no influence on biocompatibility of the final device

¹ØÓÚ±»²âÑùÆ·ÎÞ¾ú״̬µÄ³ÂÊö£®Èç¹û²âÊÔÑùÆ·²»ÊÇÎÞ¾ú£¬Ó¦¸ø³öÃð¾ú¶Ô³ÉÆ·µÄÉúÎïÏàÈÝÐÔ²»Æð×÷ÓõÄÔ­ÒòµÄ»ù±¾Ô­Àí£®

??Assign appropriate tests to the biological effects. (Only such tests shall be performed which lead to evident results)Ö¸¶¨Êʵ±µÄ²âÊÔÀ´²âÊÔÉúÎïÐÔЧӦ£¨Ö»½øÐдËÀàÄܲúÉúÃ÷ÏÔ½á¹ûµÄ²âÊÔ£©

o Overview of tests to be performed in biological evaluationÔÚÉúÎïѧÆÀ¼ÛÖÐËù½øÐеIJâÊԵĸŹÛ

??The selection and evaluation of any material or device intended for use in humans requires a structured programme of assessment (refer to ISO 10993-1 Annex B)

ÓÃÓÚÈËÌåµÄÈκβÄÁÏ»òÆ÷еµÄÑ¡ÔñºÍÆÀ¹ÀÐèÒª½á¹¹»¯µÄÆÀ¹À³ÌÐò£¨²Î¼ûISO 10993-1Öи½Â¼£Â£©

o Justification for tests not performedδ½øÐеIJâÊÔµÄ֤ʵ

??The quality and the extent of documentation as well as the assessment in regard to the intended use determine whether or not biological tests shall be performed with the final product and to what extent

¹ØÓÚÔ¤ÆÚÓÃ;µÄÎļþ²ÄÁϵÄÖÊÁ¿ºÍ·¶Î§ÒÔ¼°ÆÀ¹À¾ö¶¨ÁËÊÇ·ñ¶Ô³ÉÆ·½øÐÐÉúÎï²âÊÔ£¬ÒÔ¼°½øÐе½Ê²Ã´³Ì¶È£®

??Biological evaluation may include both a study of relevant experience and actual testing. Such an evaluation may result in the conclusion that no testing is

needed if the material has a documented history of use in a specified role that is equivalent to that of the device under design

ÉúÎïÆÀ¹À°üÀ¨Ïà¹Ø¾­ÑéºÍʵ¼Ê²âÊÔµÄÑо¿£®ÕâÑùµÄÆÀ¹À¿ÉÄܵ¼ÖÂÒÔϵĽáÂÛ£º

Èç¹û²ÄÁÏÓÐÎļþ»¯µÄʹÓÃÀúÊ·²¢ÔÚÖ¸¶¨µÄ×÷Ó÷½ÃæµÈͬÓÚÕýÔÚÉè¼ÆÖÐµÄÆ÷еµÄʹÓÃÀúÊ·£¬ÄÇô²»ÐèÒª²âÊÔ£®

??Each device should be examined on its own features. Data may be available

from suppliers or in the literature. In this case full transferability is to be demonstrated. Test systems, test sensitivity and concentrations used should be taken into consideration

ÿÖÖÆ÷еӦ¸ù¾ÝÆä×ÔÉíµÄÌØÕ÷½øÐмì²é£®¿É´Ó¹©Ó¦ÉÌ»òÎÄÏ×ÖлñµÃÊý¾Ý£®ÔÚ´ËÖÖÇé¿öÏ£¬½«Õ¹Ê¾ÍêÈ«µÄ¿É×ªÒÆÐÔ£®Ó¦¿¼Âǵ½ÓùýµÄ²âÊÔϵͳ£¬²âÊÔÃô¸ÐÐÔºÍŨ¶È£® ??Waiving of tests shall be recordedÆúȨµÄ²âÊÔÓ¦¼Ç¼

??Biocompatibility test protocols (copies) ÉúÎïÏàÈÝÐÔ²âÊÔЭÒé(¸´Ó¡¼þ) o Qualification of the test laboratory, i.e. accreditation²âÊÔʵÑéÊÒµÄ×ʸñÑéÖ¤£¬¼´ÈÏÖ¤ o Testing should be conducted according to appropriate good laboratory practices followed by evaluation by competent informed persons

²âÊÔÓ¦°´ÕÕÊʵ±µÄÁ¼ºÃʵÑéÊҹ淶½øÐУ¬È»ºóÓÉȨÍþµÄÖªÇéÈËÊ¿½øÐÐÆÀ¹À o For qualitative data: acceptance criteria¶ÔÓÚ¶¨ÐÔÊý¾Ý£ºÑéÊÕ×¼Ôò ??Biocompatibility test reports (copies) ÉúÎïÏàÈÝÐÔ²âÊÔ±¨¸æ£¨¸´Ó¡¼þ£© o For qualitative data/results: interpretation¶ÔÓÚ¶¨ÐÔÊý¾Ý£¯½á¹û£º²ûÊö o Positive results ¨C What to do?ÑôÐÔ·´Ó¦£­Òª×öʲô£¿ ??Verification of results½á¹ûµÄÈ·ÈÏ

??Chemical characterization of leachablesÂ˳öÎïµÄ»¯Ñ§ÌØÐÔ

??Overall interpretation of the biological evaluation of the deviceÆ÷еµÄÉúÎïѧÆÀ¼ÛµÄ×ÜÌå²ûÊö

??Relevance of clinical useÁÙ´²Ê¹ÓõÄÏà¹ØÐÔ

??Biocompatibility evaluation and summary reportÉúÎïÏàÈÝÐÔÆÀ¼ÛºÍ×ܽᱨ¸æ o Compilation of tests performed in tabular formÒÔ±í¸ñµÄÐÎʽ±àÖÆ²âÊÔ ExampleÀýÈç:

Test²âÊÔ

Protocol No.ЭÒéºÅ Project No./²úÆ·±àºÅ Laboratory No.ʵÑéÊÒ±àºÅ Report date ±¨¸æÈÕÆÚ Result½á¹û Conclusion½áÂÛ Cytotoxicityϸ°û¶¾ÐÔ Cytotoxicity test /ϸ°û¶¾ÐÔ²âÊÔ L 929-proliferation L 929-À©É¢ XY yyyy-mm-ddÄ꣭Ô£­ÈÕ Growth analysis of cells cultured with the test extract showed no relevant growth inhibition of L929 cells.

²âÊÔÌáÈ¡µÄÅàÑøÏ¸°ûµÄÉú³¤·ÖÎöδÏÔʾÏà¹ØµÄL929ϸ°ûµÄÉú³¤ÒÖÖÆ SensitizationÖÂÃôÐÔ

Murine Local LymphÊóÐÔÊóÐÔÊóÐÔ¾Ö²¿ÁÜ°Í Node Assay½Úµã»¯Ñé YZ yyyy-mm-dd Ä꣭Ô£­ÈÕ The stimulation indices were

calculated to be less than 3.0. ´Ì¼¤Ö¸ÊýÒªÉÙÓÚ3.0.

o Further relevant information on the testsÓйزâÊԵĸü¶àÏà¹ØÐÅÏ¢

??Test sample (part tested) e.g. catheter shaft or tip, balloon, whole device ÊÔÑù£¨²¿·Ö²âÊÔ£©ÀýÈ磺¹Ü¸Ë»òµ¼¹Ü¼â¶Ë£¬ÆøÄÒ£¬Õû¸öÆ÷е

??Specification (polymer type, supplier, trade name, additives) e.g. PUR, Pellethane 2363-90A, 20% Ba2SO4

¹æ¸ñ£¨¾ÛºÏÎïÀàÐÍ£¬¹©Ó¦ÉÌ£¬ÉÌÆ·Ãû£¬Ìí¼Ó¼Á£©ÀýÈ磺PUR, Pellethane 2363-90A, 20% Ba2SO4

??Status of test material (final product, sterile)

²âÊÔ²ÄÁÏ״̬£¨³ÉÆ·£¬ÎÞ¾ú£©

??Type of body contact e.g. circulating blood ÉíÌå½Ó´¥ÀàÐÍ ÀýÈ磺ѪҺѭ»·

??Contact duration e.g. limited contact duration (< 24 h) ½Ó´¥³ÖÐøÊ±¼ä ÀýÈ磺ÏÞ¶¨µÄ½Ó´¥³ÖÐøÊ±¼ä£¨£¼24Сʱ) ??Standard/norm e.g. EN ISO 10993-5: 1999 ±ê×¼£¯¹æ·¶ ÀýÈ磺EN ISO 10993-5: 1999

??Extract preparation (medium, surface/mass to volume ratio, temperature, time) Ìáȡ׼±¸£¨Ã½½é£¬±íÃæ£¯ÖÊÁ¿Ìå»ý±È£¬Î¶ȣ¬Ê±¼ä£©

??Test lab qualification e.g. competence under DIN EN ISO/IEC 17025, certification acc. to GLP

²âÊÔʵÑéÊÒ×ʸñ ÀýÈ磺 DIN EN ISO/IEC 17025µÄ×ʸñÈÏÖ¤£¬ÒÀ¾ÝGLPµÄÈÏÖ¤ ??Action taken on positive results as described above ÉÏÊöµÄ¶ÔÑôÐÔ·´Ó¦²ÉÈ¡µÄ´ëÊ© o Conclusion½áÂÛ

??Biological evaluation shall be part of the risk management process ÉúÎïѧÆÀ¼ÛÓ¦ÊÇ·çÏÕ¹ÜÀí¹ý³ÌµÄÒ»²¿·Ö£®

??A final statement of the manufacturer is necessary. The manufacturer might conclude that in his opinion, based on the submitted documentation, the product safety is ensured

Éú²úÉ̵Ä×îÖÕ³ÂÊöÊDZØÒªµÄ£®Éú²úÉÌ¿ÉÄܸù¾Ý×Ô¼ºµÄÒâ¼û£¬ÔÚËùÌá½»µÄÎļþ²ÄÁÏ»ù´¡Éϵóö²úÆ·°²È«ÊÇÊܵ½±£ÕϵĽáÂÛ£®

4.4 Bio-stability TestsÉúÎïÎȶ¨ÐÔ²âÊÔ

Influence of the biological matrix on the device, i.e. ÉúÎï»ùÖÊ¶ÔÆ÷еµÄÓ°Ï죬¼´ ??Surface Stress Cracking on Polymers¸ß·Ö×Ó²ÄÁϵıíÃæÓ¦Á¦¶ÏÁÑ ??Corrosion of load-bearing metal screws³ÐÖØ½ðÊôÂÝË¿µÄ¸¯Ê´ÐÔ ??Coating StabilityÍ¿²ãÎȶ¨ÐÔ

4.5 Microbiological Safety, Animal Origin tissue΢ÉúÎﰲȫ, ¶¯ÎïÔ´ÐÔµÄ×éÖ¯

??Geographical origin and boarding of animals: Species, Country, Herd, Feeding, Age ¶¯ÎïµÄµØÀíÀ´Ô´£ºÎïÖÖ£¬¹ú¼Ò£¬ÊÞȺ£¬ËÇÑø£¬ÄêÁä ??Origin of material used/nature of starting tissue: ËùÓòÄÁÏÀ´Ô´£¯×éÖ¯µÄÐÔÖÊ

??Specified risk material: organ, tissue, body fluid Ö¸¶¨Î£ÏÕÎïÖÊ£ºÆ÷¹Ù£¬×éÖ¯£¬ÈËÌåÁ÷Ìå

??For TSE-relevant species: If available certificate of suitability of starting materials with respect to TSE issued by EDQM ¶ÔÓÚÓ봫ȾÐÔº£Ãà×´ÄÔ²¡Ïà¹ØµÄÎïÖÖ£ºÈç¹û¿É»ñµÃÓëÓÉEDQMÇ©·¢µÄ´«È¾ÐÔº£Ãà×´ÄÔ²¡Ïà¹ØµÄÔ­²ÄÁϵÄÊÊÓÃÐÔÖ¤Êé ??Veterinary controls¶¯Îï¿ØÖÆ

??Certificate demonstrating conformance with veterinary inspection criteria indicating that the raw material was fit for human consumption.

·ûºÏָʾԭ²ÄÁÏÊʺÏÈËÀàÏû·ÑµÄÊÞҽѧ¼ì²â±ê×¼µÄÖ¤Ã÷Ö¤Êé

??Certificate documenting that the applied techniques for stunning and slaughtering were suitable to avoid cross contamination with specified risk material.(References:

EN 12442-2/SSC guidelines/EC decisions.)

ÊÊÓü¼ÊõÊʺϱÜÃâÓë¹æ¶¨µÄΣÏÕÎïÖʽ»²æÎÛȾµÄÖ¤Êé¼Ç¼.£¨²Î¼û£ºEN 12442-2/SSC Ïòµ¼/EC¾ö¶¨£©

Risk analysis·çÏÕ·ÖÎö

??Risk analysis performed according to EN 14971 and EN 12442-1, including immunological,

toxicological, and liquid sterilization risks.

°´ÕÕEN 14971ºÍEN 12442-1Ëù½øÐеķçÏÕ·ÖÎö,°üÀ¨ÃâÒßѧµÄ,¶¾ÎïѧµÄ, ÒºÌåɱ¾ú·çÏÕ.

??Sum of Category Numbers (SCN) for TSE-relevant material only obtained according to

the following scheme

Ó봫ȾÐÔº£Ãà×´ÄÔ²¡Ïà¹ØµÄÎïÖʵÄÀà±ð±àºÅ×ܸŽö¸ù¾ÝÒÔϵÄģʽ°üº¬ÔÚÄÚ:

Parameter Numbers of Risk categories·çÏÕÀà±ðµÄ²ÎÊý±àºÅ 1 2 3 4 CN GBR IV Incidence·¢ÉúÂÊ < 1:10000 GBR III

Incidence·¢ÉúÂÊ < 1:1 million°ÙÍò GBR II OthersÆäËü GBR I No BSE, no Risk·çÏÕ Geographical OriginµØÀíÀ´Ô´

Specified risk High risk Medium risk Low risk No risk¹æ¶¨µÄ·çÏÕ ¸ß·çÏÕ ÖеȷçÏÕ µÍ·çÏÕ ÎÞ·çÏÕ

Material ÎïÖÊ

Inactivation¶Û»¯ NoneÎÞ 2-4 log 4-6 log > 6 log Quantity/dose > 100 g 1-100 g 10 mg ¨C 1 g < 10 mg of raw material

Ô­²ÄÁϵÄÊýÁ¿/¼ÁÁ¿ > 100 g 1-100 g 10 mg ¨C 1 g < 10 mg Intracerebral´óÄÔÄÚµÄOther parenteral ÆäËü³¦Î¸ÍâµÄ Mucous membraneð¤Ä¤

Route of administration¸øÒ©Í¾¾¶ External skinÍⲿƤ·ô

Sum of Category Numbers (SCN) Àà±ð±àºÅ»ã×Ü:

Sum of Category Numbers (SCN) Significance and ConsequencesÀà±ð±àºÅ»ã×ÜÒâÒåºÍ

ºó¹û

20 Highest possible score, virtually no risk 20×î¸ßµÄ¿ÉÄܵ÷Ö, ×îÖÕÎÞ·çÏÕ

  • ÊÕ²Ø
  • Î¥¹æ¾Ù±¨
  • °æÈ¨ÈÏÁì
ÏÂÔØÎĵµ10.00 Ôª ¼ÓÈëVIPÃâ·ÑÏÂÔØ
ÍÆ¼öÏÂÔØ
±¾ÎÄ×÷Õߣº...

¹²·ÖÏí92ƪÏà¹ØÎĵµ

Îĵµ¼ò½é£º

taken from the final product or from materials processed in the same manner as the final product (if applicable provide LOT/REF. No., etc.) ¶Ô´Ó³ÉÆ·Öлò´ÓÒÔͬÑùµÄ·½Ê½½øÐд¦ÀíµÄ²ÄÁÏÖгé³öµÄ³ÉÆ·»ò´ú±íÐÔÑùÆ·¾ªÐѲâÊÔ(Èç¹ûÊÊÓÃ,ÌṩÅúºÅ/²Î¿¼±àºÅµÈµÈ) ??Rationale for the selection of the sample tested±»²âÑùÆ·Ñ¡ÔñµÄ»ù±¾Ô­Àí ??Statement on the sterile state of the test sample. If the test sample was not sterilized, a rationale shall be given

¡Á ÓοͿì½ÝÏÂÔØÍ¨µÀ£¨ÏÂÔØºó¿ÉÒÔ×ÔÓɸ´ÖƺÍÅŰ棩
µ¥Æª¸¶·ÑÏÂÔØ
ÏÞÊ±ÌØ¼Û£º10 Ôª/·Ý Ô­¼Û:20Ôª
VIP°üÔÂÏÂÔØ
ÌØ¼Û£º29 Ôª/Ô ԭ¼Û:99Ôª
µÍÖÁ 0.3 Ôª/·Ý ÿÔÂÏÂÔØ150·Ý
ȫվÄÚÈÝÃâ·Ñ×ÔÓɸ´ÖÆ
VIP°üÔÂÏÂÔØ
ÌØ¼Û£º29 Ôª/Ô ԭ¼Û:99Ôª
µÍÖÁ 0.3 Ôª/·Ý ÿÔÂÏÂÔØ150·Ý
ȫվÄÚÈÝÃâ·Ñ×ÔÓɸ´ÖÆ
×¢£ºÏÂÔØÎĵµÓпÉÄÜ¡°Ö»ÓÐĿ¼»òÕßÄÚÈݲ»È«¡±µÈÇé¿ö£¬ÇëÏÂÔØÖ®Ç°×¢Òâ±æ±ð£¬Èç¹ûÄúÒѸ¶·ÑÇÒÎÞ·¨ÏÂÔØ»òÄÚÈÝÓÐÎÊÌ⣬ÇëÁªÏµÎÒÃÇЭÖúÄã´¦Àí¡£
΢ÐÅ£ºfanwen365 QQ£º370150219
Copyright © ÔÆÌ⺣ All Rights Reserved. ËÕICP±¸16052595ºÅ-3 ÍøÕ¾µØÍ¼ ¿Í·þQQ£º370150219 ÓÊÏ䣺370150219@qq.com